search
Back to results

Colorectal Cancer Screening Based on Predicted Risk (PRESENT)

Primary Purpose

Colorectal Cancer

Status
Active
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Intervention brochure
Control brochure
Sponsored by
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Colorectal Cancer focused on measuring Colorectal Cancer Screening, Personalized Risk, Risk Communication, Shared Decision Making, Screening Behavior

Eligibility Criteria

50 Years - 69 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Aged between 50 and 69;
  • Residents of the Canton of Vaud;
  • Have signed an informed consent (paper or electronic).

Exclusion Criteria:

  • Current CRC symptoms;
  • Personal CRC history;
  • In colonoscopy surveillance for follow-up of high-risk polyp(s);
  • Inflammatory bowel disease;
  • Having done a colonoscopy within 9 years or a FIT within 1,5 years;
  • Planning to leave Switzerland definitively within the next six months.

Sites / Locations

  • Center for Primary Care and Public Health (Unisante)

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intervention group

Usual care group

Arm Description

Participants in the Intervention group receive a brochure with their personalized risk score for colorectal cancer and screening recommendations (FIT or colonoscopy) corresponding to their risk level.

Participants in the Usual care group receive the standard brochure designed by the Vaud screening program. This brochure recommends screening to all individuals beginning at age 50 and presents both FIT and colonoscopy as equal options.

Outcomes

Primary Outcome Measures

Self-reported appropriate screening uptake
Proportion who completed screening test appropriate to risk level. For low risk (<3% 15-yr CRC risk), completing a FIT. For intermediate risk (3-6%15-yr CRC risk), completing a FIT, completing a colonoscopy, or having a colonoscopy appointment. For high risk (>6% 15-yr CRC risk), completing a colonoscopy or having a colonoscopy appointment.

Secondary Outcome Measures

Self-reported overall screening participation
Proportion who completed any CRC screening test (FIT, colonoscopy, colonoscopy appointment, CT colonography, blood test, etc.
Participation in the randomized trial
Proportion of those invited with completed paper or electronic consent
Eligibility for the Vaud CRC screening program
Proportion of those who returned the baseline questionnaire who are eligible for the Vaud screening program (i.e. not up-to-date with screening, not in colonoscopy surveillance, no personal CRC history, etc.)
Self-reported anxiety
Mean anxiety score using adapted questions from a standardized questionnaire (STAI Fr)
Linkage to Vaud CRC screening program
Proportion of study participants who consent and whose screening status are obtained from the Vaud CRC screening program
Linkage to Vaud tumor registry
Proportion of study participants who consent and whose cancer status are obtained from the Vaud tumor registry. Long time frame chosen given considerable delay in updating the tumor registry and interest in cancer outcomes several years after measurement of primary outcome.

Full Information

First Posted
April 19, 2022
Last Updated
October 6, 2023
Sponsor
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
search

1. Study Identification

Unique Protocol Identification Number
NCT05357508
Brief Title
Colorectal Cancer Screening Based on Predicted Risk
Acronym
PRESENT
Official Title
Protocol Title: Colorectal Cancer Screening Decisions Based on Predicted Risk: the PREcision ScreENing Randomized Controlled Trial (PRESENT)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
May 1, 2022 (Actual)
Primary Completion Date
July 31, 2023 (Actual)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective is to study the effect of communicating individual CRC risk score and screening recommendations on appropriate screening uptake at six months in individuals at low, moderate and high risk of developing CRC. The secondary objectives: Assess the feasibility of a subsequent larger RCT designed to detect a change in clinical outcomes; Explore the impact of psychological factors (perceived susceptibility for CRC, perceived benefits from and barriers to screening) on appropriate screening uptake and participation rates. The investigators will perform a pilot randomized controlled trial (RCT) of 880 residents from the canton Vaud (Switzerland) aged between 50 and 69 years. The QCancer calculator will be used to calculate the personalized risk score. The participants in the intervention group will receive a brochure with a personalized risk score and appropriate screening recommendations. The participants in the control group will receive the standard brochure of the Vaud CRC screening program, regardless of participants' risk level. Six months after the intervention, the investigators will measure the proportion of the participants who have undergone appropriate screening. Screening will be considered as appropriate if participants at high risk undertake colonoscopy and participants at low risk undertake FIT. Both tests are appropriate for participants at moderate-risk. The hypothesis is that in the intervention group, individuals will be more likely to undergo screening appropriate to a participant's individual risk level, whereas the choice of the screening test in the control group will not differ between risk levels. This study should advance the field of risk-based screening. This may give insights about how to optimize CRC screening programs and offer to the population screening options with a better risk-benefit balance.
Detailed Description
Colorectal cancer (CRC) can be effectively prevented by screening. Risk to develop CRC within 15 years is related to increasing age, sex, family history, and lifestyle and, thus, can vary from <1% to >15%. Fecal immunochemical test (FIT) and colonoscopy are the most widely used screening tests. Colonoscopy is the most accurate test, but is related to risks of bleeding and perforation. Colonoscopy resources are limited, and high uptake of screening colonoscopy for low-risk individuals can cause long wait times for those with CRC symptoms or positive FIT. FIT is less costly can be done at home without preparation and, if done regularly, prevents most CRC mortality, especially in moderate and low-risk individuals. To offer the screening options with a reasonable risk-benefit balance, FIT should be recommended to individuals at low (<3% to develop CRC in 15 years) and moderate (3-6%) risk, and colonoscopy to those at high (>6%) risk. The primary objective is to study the effect of communicating individual CRC risk score and screening recommendations on appropriate screening uptake at six months in individuals at low, moderate and high risk of developing CRC. The secondary objectives: Assess the feasibility of a subsequent larger RCT designed to detect a change in clinical outcomes; Explore the impact of psychological factors (perceived susceptibility for CRC, perceived benefits from and barriers to screening) on appropriate screening uptake and participation rates. The investigators will perform a pilot randomized controlled trial (RCT) of 880 residents from the canton Vaud (Switzerland) aged between 50 and 69 years. The QCancer calculator will be used to calculate the personalized risk score. The participants in the intervention group will receive a brochure with a personalized risk score and appropriate screening recommendations. The participants in the control group will receive the standard brochure of the Vaud CRC screening program, regardless of the participant's risk level. Six months after the intervention, the investigators will measure the proportion of the participants who have undergone appropriate screening. Screening will be considered as appropriate if participants at high risk undertake colonoscopy and participants at low risk undertake FIT. Both tests are appropriate for participants at moderate-risk. The hypothesis is that in the intervention group, individuals will be more likely to undergo screening appropriate to participant's individual risk level, whereas the choice of the screening test in the control group will not differ between risk levels. This study should advance the field of risk-based screening. This may give insights about how to optimize CRC screening programs and offer to the population screening options with a better risk-benefit balance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer
Keywords
Colorectal Cancer Screening, Personalized Risk, Risk Communication, Shared Decision Making, Screening Behavior

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
515 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention group
Arm Type
Experimental
Arm Description
Participants in the Intervention group receive a brochure with their personalized risk score for colorectal cancer and screening recommendations (FIT or colonoscopy) corresponding to their risk level.
Arm Title
Usual care group
Arm Type
Active Comparator
Arm Description
Participants in the Usual care group receive the standard brochure designed by the Vaud screening program. This brochure recommends screening to all individuals beginning at age 50 and presents both FIT and colonoscopy as equal options.
Intervention Type
Behavioral
Intervention Name(s)
Intervention brochure
Intervention Description
Provide participants with information about their personalized risk for colorectal cancer and appropriate screening recommendations to facilitate their screening option choice.
Intervention Type
Behavioral
Intervention Name(s)
Control brochure
Intervention Description
Provide participants with general information about options for colorectal cancer screening.
Primary Outcome Measure Information:
Title
Self-reported appropriate screening uptake
Description
Proportion who completed screening test appropriate to risk level. For low risk (<3% 15-yr CRC risk), completing a FIT. For intermediate risk (3-6%15-yr CRC risk), completing a FIT, completing a colonoscopy, or having a colonoscopy appointment. For high risk (>6% 15-yr CRC risk), completing a colonoscopy or having a colonoscopy appointment.
Time Frame
6-8 months after the intervention
Secondary Outcome Measure Information:
Title
Self-reported overall screening participation
Description
Proportion who completed any CRC screening test (FIT, colonoscopy, colonoscopy appointment, CT colonography, blood test, etc.
Time Frame
6-8 months after the intervention
Title
Participation in the randomized trial
Description
Proportion of those invited with completed paper or electronic consent
Time Frame
6 weeks after mailed invitations
Title
Eligibility for the Vaud CRC screening program
Description
Proportion of those who returned the baseline questionnaire who are eligible for the Vaud screening program (i.e. not up-to-date with screening, not in colonoscopy surveillance, no personal CRC history, etc.)
Time Frame
6 weeks after mailed invitations
Title
Self-reported anxiety
Description
Mean anxiety score using adapted questions from a standardized questionnaire (STAI Fr)
Time Frame
6 weeks after mailed invitations
Title
Linkage to Vaud CRC screening program
Description
Proportion of study participants who consent and whose screening status are obtained from the Vaud CRC screening program
Time Frame
3-6 months after measurement of primary outcome
Title
Linkage to Vaud tumor registry
Description
Proportion of study participants who consent and whose cancer status are obtained from the Vaud tumor registry. Long time frame chosen given considerable delay in updating the tumor registry and interest in cancer outcomes several years after measurement of primary outcome.
Time Frame
6 months to 10 years after measurement of primary outcome

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Aged between 50 and 69; Residents of the Canton of Vaud; Have signed an informed consent (paper or electronic). Exclusion Criteria: Current CRC symptoms; Personal CRC history; In colonoscopy surveillance for follow-up of high-risk polyp(s); Inflammatory bowel disease; Having done a colonoscopy within 9 years or a FIT within 1,5 years; Planning to leave Switzerland definitively within the next six months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kevin Selby, MD, MAS
Organizational Affiliation
Center for Primary Care and Public Health (Unisanté)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Center for Primary Care and Public Health (Unisante)
City
Lausanne
State/Province
Vaud
ZIP/Postal Code
1011
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Upon publication of the primary results, the data that support the findings of this study will be available from the corresponding author upon reasonable request.
IPD Sharing Time Frame
Will become available upon publication of the primary results and remain available 5 years.
IPD Sharing Access Criteria
Reasonable request to the principal investigator
Citations:
PubMed Identifier
25783428
Citation
Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study. BMJ Open. 2015 Mar 17;5(3):e007825. doi: 10.1136/bmjopen-2015-007825.
Results Reference
background
PubMed Identifier
35353458
Citation
Samusure J, Horisberger D, Diserens C, Ducros C, Auer R, Bodenmann P, Durand MA, Selby K. [Information materials for colorectal cancer screening for citizens with low health literacy]. Rev Med Suisse. 2022 Mar 30;18(775):616-620. doi: 10.53738/REVMED.2022.18.775.616. French.
Results Reference
background
PubMed Identifier
37676720
Citation
Plys E, Bulliard JL, Chaouch A, Durand MA, van Duuren LA, Brandle K, Auer R, Froehlich F, Lansdorp-Vogelaar I, Corley DA, Selby K. Colorectal Cancer Screening Decision Based on Predicted Risk: Protocol for a Pilot Randomized Controlled Trial. JMIR Res Protoc. 2023 Sep 7;12:e46865. doi: 10.2196/46865.
Results Reference
background
Links:
URL
https://www.unisante.ch/fr/formation-recherche/recherche/projets-etudes/etude-sur-choix-test-depistage-du-cancer-du-colon
Description
Study website
URL
https://qcancer.org/15yr/colorectal/index.php
Description
Risk calculator used

Learn more about this trial

Colorectal Cancer Screening Based on Predicted Risk

We'll reach out to this number within 24 hrs